Agenus Inc.
NASDAQ:AGENBiotechnology
-$0.01 today
- Market cap
- $289.58M
- Beta
- 1.54
- P/E (TTM)
- 1.7
- EPS (TTM)
- $1.70
Volume 0.88M
Average 0.82M
AGEN Operating Cash Flow
Cash generated by the company's core business operations during the period.
Agenus Inc.NASDAQ: AGEN
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $35.95M (cash outflow) rose 40.3% year over year, ahead of the -39.9% change in trailing-twelve-month operating cash flow. Sequentially, it rose 116.3% from the prior quarter. Over 3 fiscal years it compounded at -3.4% a year.
Context
- Operating cash flow amounted to 138.6% of revenue in FY2025, down 14.4 pp from a year earlier.
- Operating cash flow grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +40.3% holds above the trailing-twelve-month pace of -39.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (158.32M) USD
- Year-over-year change
- +0.0%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (158.32M) | +0.0% |
| FY2024 | 2024-12-31 | (158.32M) | +29.4% |
| FY2023 | 2023-12-31 | (224.2M) | -27.8% |
| FY2022 | 2022-12-31 | (175.37M) | -1828.7% |
| FY2021 | 2021-12-31 | 10.15M | — |
Operating Cash Flow vs competitors
How AGEN compares with its peers on the latest reported figures
- AGEN's LTM Mar 2026 operating cash flow of $87.53M is the 5th largest of the 10 companies compared; the peer median is $83.35M.
- Its year-over-year change of -39.9% is the 7th highest of 8, against a peer median of -16.4%.
- Operating cash flow amounts to 70.7% of revenue for AGEN, versus a peer median of 325.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $125.57M | -17.1% | -8.5% | — | |
| LTM Mar 2026 | $105.55M | +3.0% | +48.7% | — | |
| LTM Mar 2026 | $103.1M | -16.4% | -24.7% | 1632.3% | |
| LTM Mar 2026 | $98.7M | -43.3% | +10.7% | — | |
| LTM Mar 2026 | $87.53M | -39.9% | -3.4% | 70.7% | |
| LTM Mar 2026 | $83.35M | -18.4% | -25.7% | — | |
| LTM Mar 2026 | $48.47M | +3.0% | -9.9% | 322.3% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $38.99M | +35.1% | — | 325.3% |
| LTM Mar 2026 | $27.3M | — | +54.4% | — | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $3.9M | — | — | — |
| Peer median (excluding AGEN) | $83.35M | -16.4% | -8.5% | 325.3% | |
Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (28.72M) | (230.66M) | (257.44M) | (232.27M) | (232.27M) |
| Depreciation & Amortization | 6.79M | 6.95M | 13.59M | 13.34M | 13.34M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 19.58M | 18.34M | 22.87M | 17.39M | 17.39M |
| Change in Working Capital | (9.74M) | 24.08M | 10.76M | 32.6M | 27.33M |
| Accounts Receivables | (394K) | 122K | (23.46M) | 25.34M | (1.73M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 10.82M | 6.49M | 21.37M | 2.01M | 23.5M |
| Other Working Capital | (20.17M) | 17.47M | 12.85M | 5.25M | 5.56M |
| Other Non-Cash Items | 22.25M | 5.92M | (13.98M) | 10.62M | 15.89M |
| Operating Cash Flow | 10.15M | (175.37M) | (224.2M) | (158.32M) | (158.32M) |
| Capital Expenditures | (33.81M) | (53.06M) | (9.95M) | (576K) | (576K) |
| Acquisitions (Net) | 0 | (2.92M) | 0 | 0 | 0 |
| Purchases of Investments | (14.99M) | (24.63M) | (20.04M) | 0 | 0 |
| Sales of Investments | 0 | 25M | 30.03M | 579K | 579K |
| Other Investing Activities | 5.66M | 22M | 3.36M | 24K | 24K |
| Investing Cash Flow | (43.15M) | (33.61M) | 3.4M | 27K | 27K |
| Debt Repayment | (1.32M) | (490K) | (8.93M) | 9.52M | 2.35M |
| Common Stock Issued | 220.65M | 99.21M | 133.16M | 38.82M | 36.31M |
| Common Stock Repurchased | (1.65M) | (3.79M) | (5.17M) | 0 | (87K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.59M | 898K | 807K | 74.5M | 84.27M |
| Financing Cash Flow | 225.26M | 95.83M | 119.87M | 122.84M | 122.84M |
| Effect of Forex Changes | (164K) | (104K) | (628K) | (260K) | (260K) |
| Net Change in Cash | 192.1M | (113.26M) | (101.56M) | (35.71M) | (35.71M) |
| Free Cash Flow | (23.67M) | (228.44M) | (234.16M) | (158.89M) | (158.89M) |
Agenus Inc.
NASDAQ:AGEN
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.